Results 101 to 110 of about 17,568,133 (310)
This cross‐species study reveals that pathological hyperactivity of BNST neurons in depressive states disrupts inhibitory period and isolated spikes in the BNST‐NAc circuit. DBS achieves its antidepressant effects by precisely restoring network inhibitory periods and high‐fidelity signal transmission.
Xin Lv +12 more
wiley +1 more source
Looking beyond Placebo-Controlled Trials [PDF]
Flohr, Carsten, Weidinger, Stephan
openaire +5 more sources
Integrating Human Intestinal Organoids into FDA'S New Approach Methodologies for Drug Discovery
Illustration summarizes how human intestinal organoids (HIOs) are becoming transformative in preclinical research. Preclinical drug discovery pipelines often rely on animal models for ADMET studies, even though interspecies ADME gaps, poor external validity, and high attrition rates are common.
Debarun Patra +6 more
wiley +1 more source
Placebo Controls: Now??? [PDF]
openaire +2 more sources
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang +6 more
wiley +1 more source
Ferroptosis: The Demise of Cells Through Phospholipid Peroxidation
The relative abundance of peroxidation‐resistant monounsaturated fatty acids (MUFAs) vs. peroxidation‐sensitive polyunsaturated fatty acids (PUFAs) incorporated into phospholipid (PL) is a key determinant of ferroptosis sensitivity, as the peroxidation of PL PUFA acyl chains (PUFA‐PL) disrupts membrane integrity, causing ferroptotic cell death ...
Shaojie Cui, Jin Ye
wiley +1 more source
Introduction: Placebo-controlled studies are crucial in clinical trials, but the placebo effect can vary across conditions. We aimed to assess the placebo effect in chronic thromboembolic pulmonary hypertension (CTEPH) trials.
Daniel Caldeira +5 more
doaj +1 more source
Nanozymes, as enzyme‐mimicking nanomaterials, exhibit unique catalytic properties for the treatment of liver diseases. By regulating redox homeostasis, modulating immune responses, and enabling targeted delivery, nanozymes overcome the limitations of natural enzymes.
Xiandi Meng +6 more
wiley +1 more source
Re-evaluation of Significance and the Implications of Placebo Effect in Antidepressant Therapy
Marko Curkovic +3 more
doaj +1 more source

